Navigation Links
FDA Classifies Recent Terumo CVS Recall of Coronary Ostia Cannulae as Class I Action
Date:6/16/2011

ANN ARBOR, Mich., June 16, 2011 /PRNewswire/ -- Terumo Cardiovascular Systems (Terumo CVS) announced today that the U.S. Food and Drug Administration has classified as a Class I action the company's recent voluntary recall of its Coronary Ostia Cannula. Terumo CVS discovered several instances of adhesive build-up and/or skiving of plastic (plastic flash) inside the distal tip of the cannula. The defect was discovered during in-house inspection after Terumo CVS implemented a new inspection process for the cannula; Terumo CVS has not received any reports of the defect in clinical use.

Coronary ostia cannulae are used to deliver cardioplegia solution to the coronary arteries during cardiac surgery.  

Excess plastic or adhesive in the cannula tip could potentially narrow the interior diameter of the tip, resulting in inadequate delivery of cardioplegia and/or a prolonged surgical procedure if the narrowing results in lowered cardioplegia flow rates. If the excess plastic or adhesive were to detach from the tip of the cannula, it could create an embolism in the coronary vasculature.  

Terumo CVS has not received any reports of patient injuries associated with this defect.

Terumo CVS decided to remove the product line from the market and discontinue further supply.  The company notified all 42 affected customers of the recall action in a written notice on May 16, 2011, advising customers to return all product for full credit. The company also identified possible alternative products from another manufacturer.

FDA has been informed of this action.

If customers have questions or would like additional information, they should contact Terumo CVS Customer Service, 1-800-521-2818.  

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax:


About Terumo Cardiovascular Systems

Terumo Cardiovascular Systems Corporation manufactures and markets medical devices for the global cardiac surgery market. The company is headquartered in Ann Arbor, Michigan with manufacturing operations in Ann Arbor; Elkton, Maryland; and Ashland, Massachusetts.  It is one of several subsidiaries of Terumo Corporation of Japan that is focused exclusively on cardiac and vascular specialties. Terumo CVS entered into consent decree with FDA regarding improvements to the Quality System at its Ann Arbor manufacturing facility. For more information, visit www.terumo-cvs.com.

About Terumo Corporation

Terumo Corporation is a premier global medical device company with annual sales of more than 3.4 billion dollars for the fiscal year ending March 31, 2010. Founded in 1921, the company develops, manufactures and distributes world-class medical devices, such as syringes, blood bags and IV solutions. Terumo has the biggest share of the world markets for angiography guide wires and perfusion products and is a leading developer of interventional products, such as catheters and stents.  For more information, visit www.terumo.com.


'/>"/>
SOURCE Terumo Cardiovascular Systems
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Reclassifies Certain Digital Mammography Devices
2. Aethlon Medical to Discuss Recent Progress at the LHA Life Sciences & Medical Technologies Virtual Conference on June 16
3. Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
4. A Recent Study by ITGs Majestic Market Research Indicates a Strong Launch for Gilenya in Spite of Its Time-Consuming Initiation Process
5. In a New Audio Interview at SmallCapVoice.com, Gerard Dab, Chairman and CEO of Visual Healthcare Corp., Provides Details Regarding Recent News
6. Applied Medical Sues Covidien, Asserting Recently Issued Universal Seal Trocar Patent
7. Instacare Corp. Board of Directors Considers Recent Merger Proposal Inadequate
8. Arena Pharmaceuticals Announces First Quarter 2011 Financial Results and Recent Developments
9. Simcere Announces Recent Progress of Qiangkes Registration
10. Webcast and Conference Call Alert: Isis Pharmaceuticals Holds Webcast to Discuss Recent Advances in its Development Pipeline
11. McDonald Hopkins Law Firm Alert: Recent Court of Appeals Decision Highlights the Need to Properly Define the Role of Sales Representatives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/24/2016)... N.J. , June 24, 2016  Collagen ... the design, development and manufacturing of collagen and ... regeneration announced today that Bill Messer ... and Marketing to further leverage the growing portfolio ... medical devices. Bill joins the Collagen ...
(Date:6/24/2016)... Research and Markets has ... 2015-2025: Applications, Technologies, Forecasts" report to their ... Electronics, Smart Skin, Structural Health Monitoring, Composite Smart ... electronics involves electronic and/or electrical components and circuits ... structures such as vehicle bodies or conformally placed ...
Breaking Medicine Technology:
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... On Friday, ... presented a Bronze Wellness at Work award to iHire in recognition of their exemplary ... part of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
(Date:6/24/2016)... ... 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ... raise to $12 an hour by 2020 and then adjusting it yearly to increase at ... the minimum wage, assure the wage floor does not erode again, and make future increases ...
(Date:6/24/2016)... ... 24, 2016 , ... Strategic Capital Partners, LLC (SCP) in ... investment capital for emerging technology companies. SCP has delivered investment events and ... more than a million dollars of capital investment for five companies. ...
Breaking Medicine News(10 mins):